Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader™ for rapid HIV testing in South Africa

Lara Noble1*, Lesley Scott1, Lynsey Stewart-Isherwood1,2,3, Seponono John Molifi2,4, Ian Sanne5, Pedro Da Silva2 and Wendy Stevens1,2

Abstract

Background: Rapid diagnostic tests (RDTs) are a cornerstone of HIV diagnosis and rely on good quality processing and interpretation, particularly in the era of test and treat. The Deki Reader (Fio Corporation®, Toronto, Ontario, Canada) is a portable device designed specifically for analysing RDTs and was selected for evaluation in South Africa in the context of HIV RDT analysis.

Methods: This study consisted of a laboratory evaluation and two-part field evaluation of the Deki Reader v100, covering two RDT testing algorithms, and an evaluation of the continuous quality monitoring through the Fionet™ web portal. Based on user feedback from the field evaluation, the device underwent hardware and software redesign, and the Deki Reader v200 was evaluated in the laboratory. Ethics approval for this evaluation was obtained from the University of the Witwatersrand Human Research Ethics Committee: M150160.

Results: The intra- and inter-device laboratory precision of the Deki Reader v100 were 98.3 and 99.2% respectively, and 99.3 and 100% for the Deki Reader v200. The laboratory concordances compared to standard-of-care reporting were 99.5 and 98.0% for the two respective models, while sensitivity and specificity were 99.5 and 99.4% for the Deki Reader v100 and 100 and 93.1% for the Deki Reader v200 respectively. Screening and confirmatory concordances in the field were 99.3 and 96.5% under algorithm 1 and 99.7 and 100% under algorithm 2. Sensitivity and specificity for the field evaluation were 99.8 and 97.7%. Overall robustness of the device was acceptable and continuous quality monitoring through Fionet™ was feasible.

Conclusions: The Deki Reader provides an option for improved and reliable quality assessment for rapid diagnosis of HIV using RDTs to enhance the quality of healthcare at the point-of-care. However, the introduction of new RDTs and modification of current algorithms necessitates ongoing and agile RDT reader adjustments, which will require cost modelling to ensure sustainability of devices implemented into national HIV programs.

Keywords: Automated rapid strip reader, Continuous quality monitoring, HIV, Rapid diagnostic test, Deki reader

* Correspondence: lara.noble@wits.ac.za

1Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

Full list of author information is available at the end of the article
Background

Rapid diagnostic tests (RDTs), with their simple strip-based technology, have been a cornerstone of disease diagnosis for decades. In many resource-limited settings, HIV diagnosis is now achieved using only RDTs, allowing for rapid scale-up of HIV testing services (HTS) [1], in an effort to meet the 90–90-90 [2] and ultimately 95–95-95 [3] goals. Closely linked to this are the game-changing studies showing the value of early antiretroviral therapy (ART) initiation [4–6], which ultimately led the World Health Organisation (WHO) to recommend a universal test and treat (UTT) program for HIV [7]. This initiative has been adopted by 93% of low- and middle-income countries and by 100% of the designated ‘fast-track’ countries [8], including South Africa [9]. Ongoing maintenance of the quality of rapid HIV diagnosis is critical and difficult to achieve at scale within current programs.

In addition to robust manufacturing, RDTs rely on good quality processing and interpretation. A recent systematic review [1] showed that suboptimal testing strategies, failure to follow algorithms, human error and inadequate supply chain management, amongst others, contribute to misdiagnosis globally. This analysis of 25 studies showed that users frequently perform or interpret the RDTs incorrectly, with some studies describing the use of expired RDTs [1]. Furthermore, RDT interpretation is subjective due to errors associated with visual interpretation [10, 11]. A South African evaluation by Strategic Evaluation, Advisory & Development (SEAD), a local non-governmental organisation, showed that test results were often read too early, with an overall process compliance if not immediately HIV positive of 3.4% nationally, with extreme non-compliance in KwaZulu Natal (9.7%) and Limpopo (8.6%) provinces [12], both of which have high prevalence of HIV. A recent audit of selected South African clinics showed that RDT testing practices were poor, with algorithm non-adherence, a lack of external quality control, and a lack of understanding when results were discordant, all of which may compromise the quality of the results [13].

The WHO recommends that all HIV testing sites participate in external quality assessment programmes, involving regular observation of RDT performance by trainers or supervisors, and evaluation of well-characterised HIV specimens [14, 15]. Dried tube specimens can be distributed for proficiency testing [16–18], but they may not reach all HST testers [19]. However, in a setting such as South Africa, with 270,000 (240,000–300,000) new HIV diagnoses in 2017 alone [20, 21], the HTS programme is massive and dispersed over a wide geographical area, making these forms of quality monitoring extremely difficult with poor overall impact. Given this information, it is clear that improved quality measures are required for HTS, particularly in remote areas where quality management of proficiency testing may be lacking or impractical to deliver. Jani and Peter (2013) described how connecting devices at point-of-care (POC) to the central laboratory could allow for better monitoring of results and quality [22]. An opinion piece by Wedderburn et al. (2015) discussed how the use of an electronic reader could improve the quality of RDT results, allow for capture of data for surveillance and possibly linkage to stock monitoring [23].

There are a number of automated RDT analysers available, some linked to specific RDT brands and some with the potential to adapt to different RDTs. Applications created for smartphones are also available and are increasingly used by self-testers. One such device is the Deki Reader (Fio Corporation®, Toronto, Ontario, Canada), a portable device designed specifically for analysing RDTs and utilising smartphone technology (Fig. 1a). The agile software can be programmed for any number of RDTs and in-country diagnostic algorithms. The device can also be configured to provide step-wise guidance for RDT preparation and allows two-way communication between the tester and centralised assistance providers. Results, together with captured images of the RDT, are uploaded through a proprietary web portal, Fionet™, which allows data to be centralised and monitored on a continuous basis [24]. The Deki Reader has been evaluated for assessment of malaria RDTs and was shown to be comparable with visual RDT analysis [25–31], and the Fionet™ portal was recently shown to improve malaria diagnosis by enabling improved quality monitoring [24]. A recent study in Sierra Leone linking febrile illness to HIV used the Deki Reader to capture and upload the HIV RDT results [32]. However, no extensive evaluation of the Deki Reader for HIV RDT assessment in field settings (its intended use) is available. The authors hence performed a laboratory and field evaluation of the Deki Reader, including the use of the device as a tool for continuous quality monitoring, in Johannesburg (Gauteng province, South Africa).

Methods

This evaluation consisted of four parts, summarised in Fig. 2: (1) a laboratory evaluation and (2) a two-part field evaluation of the Deki Reader v100, (3) a second laboratory evaluation of an updated device (Deki Reader v200) and (4) an evaluation of the continuous quality monitoring through the Fionet™ web portal. The device underwent a physical redesign based on feedback from the first field evaluation, leading to the second laboratory evaluation to ensure continued accuracy and precision.

A target product profile (TPP) for automated RDT analysis devices was also designed. While this was not definitive, the Deki Reader was compared to this TPP to determine needs met within the testing environment. A
critical future element for inclusion in the TPP is costing, which was beyond the scope of this evaluation.

Ethics approval
Ethics approval for this evaluation (laboratory and field) was obtained from the University of the Witwatersrand (Johannesburg, South Africa) Human Research Ethics Committee (laboratory evaluation and field evaluation: M150160). All specimens used were considered to be residual specimens as no specimens were obtained specifically for the evaluation and results from the Deki reader were not used for patient management.

Laboratory evaluation
All laboratory evaluations were performed in the Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa. Different RDTs were used in the two evaluations, based on changing national algorithms. RDTs used for the Deki Reader v100 evaluation (n = 774 specimens) were the First Response® HIV 1–2-0 (Premier Medical Corporation Limited, Daman, India; n = 253), the Determine™ HIV-1/2 Ag/Ab Combo (Alere Inc., Waltham, Massachusetts, USA; n = 259) or the Uni-Gold™ HIV (Trinity Biotech, Bray, County Wicklow, Ireland; n = 262). RDTs used for the Deki Reader v200 evaluation (n = 158 specimens) were the First Response® HIV 1–2-0 (Premier Medical Corporation Limited, Daman, India; n = 158), the HIV 1/2/0 TriLine (Abon™ BioPharm Co. Ltd., Hangzhou, China; n = 158)) and the OneStep Anti-HIV 1&2 (Guangzhou Wondfo Biotech Co. Ltd., Guangzhou, China; n = 158). Data was adjudicated by Fio as part of the software learning process and this data is presented.

For each evaluation, residual blood specimens with a known HIV status were obtained from the National Health Laboratory Service (NHLS) CD4 Flow Cytometry Laboratory (University of the Witwatersrand Medical School, Johannesburg, South Africa) and the NHLS Pathology Laboratory (Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa). RDTs were prepared according to manufacturer instructions and evaluated (read) by a laboratory professional. The
visual (user or standard of care (SOC)) result was manually captured onto the Deki Reader and uploaded to Fionet™. The RDT was then inserted into the Deki Reader for automated analysis; this result was automatically uploaded to Fionet™. The two analyses were compared to assess the concordance between visual and automated interpretation, using the visual (SOC) result as the gold standard.

Further to this, precision analyses were performed using both HIV positive and HIV negative specimens. The Deki Reader v100 was tested using five different specimens per RDT \( (n=3) \) and each RDT was read three times per each of three Deki Reader v100 instruments. The Deki Reader v200 was tested using ten different specimens that were tested on each RDT \( (n=3) \), with each RDT being read five times on one instrument and once across five different Deki Reader v200 instruments. The latter protocol introduced more stringent precision analysis to assist the developer for improved software optimisation as a lesson learnt during the v100 evaluation.

**Field evaluation**

The field evaluation was performed in collaboration with a local non-governmental organisation, Right to Care...
(Johannesburg, South Africa), between 5 May 2017 and 9 April 2018. Six key performance indicators were selected for this evaluation: (1) overall robustness of the Deki Reader, (2) efficient record upload speed, (3) connectivity needs and reliability, (4) quality data capturing concordance between visual and automated result interpretation, and (5) end-user (HCW) acceptance of the Deki Reader. HCWs and programme staff involved in the field evaluation attended a two-day training workshop, which included an introduction to the Deki Reader v100 hardware and software, and hands-on testing using the Deki Reader v100. Project managers received further training in the Fionet™ web portal software, learning how to remotely monitor and interact with the HCWs; filter data, reports and queries; and to manage quality related issues, including troubleshooting during RDT processing.

All patients attending the clinics for HIV testing services (HTS) were informed of the study and, whether or not they elected to enrol, were managed according to the South Africa National HIV Guidelines [32] and the more recently adopted WHO ART guidelines [33]. HCW performed HTS as per SOC and residual RDTs were inserted into the Deki Reader v100 for testing, with results being available for neither the HCW nor the patient. The patient was required to wait for the HCW to enter their data onto the device and for the blank RDT to be captured before testing, as well as to wait for their test result (visual read), which also needed to be captured onto the Deki Reader immediately to adhere to test time parameters (Fig. 1b). These residual RDTs were assigned random study numbers by the HCW to ensure no linkage to patient data and visual results were captured onto the device. The RDTs were then inserted into the device and a high-resolution (5MP) image captured for automated analysis. All data were automatically uploaded to the Fionet™ portal.

The first part of the evaluation (phase 1: 5 May to 5 October 2017) assessed the suitability of the Deki Reader to withstand field conditions and the connectivity needs for reliable data transfer (indicators 1 to 3), as well as HCW acceptance (indicator 4). Three HTS clinics (Johannesburg Health District, Gauteng, South Africa) participated in this evaluation (n = 20 Deki Reader v100 devices) and 23 HCWs were trained. Themba Lethu Clinic (Helen Joseph Hospital, Johannesburg) is a fixed HTS clinic and had eight devices installed. The other participants were mobile HTS clinics servicing two different regions within the Johannesburg Health District and were managed by community teams; each were allocated six devices. The RDT testing workflow followed the algorithm stipulated in the HIV testing services policy (6), which was HIV screening using the Advanced Quality™ Rapid HIV (1&2) Test (InTec PRODUCTS, Inc., Xiamin, China) and HIV positivity confirmed using the ABON™ HIV 1/2/0 Tri-line Human Immunodeficiency Virus Rapid Test Device (Abon Biopharm (Hangzhou) Co., Ltd., Hangzhou, China). The uploaded images were used for device ‘training’ and automated reporting was not available for this phase. Information regarding the record upload speed (acceptability criteria > 90% in < 10 min), and robustness of the instrument in the field (system failures) was captured from the Fionet™ portal. All data was stored on the Fio Corporation server with restricted access.

The second part of the field evaluation (phase 2: 8 October 2017 to 9 April 2018) assessed the quality of the data recorded (acceptability criteria > 95% data fields captured by the HCW; 10% of records checked), including error rates and invalid results obtained, the concordance between the visual and automated RDT assessments, and the HCW acceptance of the Deki Reader v100 (indicators 4 to 6). Eight sites, with a total of 23 Deki Reader v100 devices, participated in this evaluation: Diepsloot Clinic, Eyethu Clinic, Hillbrow Clinic, OR Thambo Clinic, Themba Lethu Clinic, Windsor Clinic, Yeoville Clinic and the Dreams Team Mobile HTS clinic. In total, 52 HCWs had training to participate in this evaluation.

Software was upgraded between phase 1 and phase 2 to allow for automated result reporting and algorithm enforcement by the Deki Reader v100, through the use of an onscreen job aid. The HCW was obliged to acknowledge the procedures performed and automated RDT assessment was not possible if the algorithm procedures were not followed. After entering the visual result, the RDT was inserted into the device for image capture and automated assessment. When a screening result was recorded as HIV-positive, the HCW was prompted to continue to confirmatory screening, following the same process. The HCW could not access the automated analysis results to ensure ongoing SOC and the HCW visual result call (gold standard) was used for patient management.

There was a change to the HTS algorithm mid-evaluation when the Gauteng Department of Health RDT supplier was changed as per tender RT41–2017 [33]. The HTS algorithm used from 8 October to mid-December 2017 used the Advanced Quality Anti-HIV (1&2) Test Card (Advanced Quality; Intec, Haicang Xia- men, China) for HIV screening, followed by result confirmation with the ABON™ HIV 1/2/0 Tri-Line Human Immunodeficiency Virus Rapid Test. The HTS algorithm used in Gauteng from December 2017 uses ABON™ HIV 1/2/0 Tri-Line Human Immunodeficiency Virus Rapid Test for screening, followed by confirmation with the First Response® HIV 1–2-0 Card Test (First Response; Premier Medical Corporation Ltd., Daman, India). There were delays implementing the December 2017 algorithm
change as clinics used up their existing RDT stocks before commencement of the new (all clinics were using the modified algorithm by February 2018). Furthermore, the manufacturer of the Abon RDT modified the printing of the cartridge in December and the RDT could not be recognised by the device. A single software upgrade to allow for the new cartridge design and the new algorithm was required, and became available on 02 February 2018.

End-user surveys were conducted both pre- and post-implementation to determine the HCWs’ perceptions of the usability and performance of the Deki Reader. To eliminate biases, researchers issued the structured questionnaires to managers who administered them to all the end-users. The end-users were asked to rank the Deki Readers based on the perceived usefulness and ease-of-use during testing using a Likert-scale [34] (quantitative analysis). The questionnaire also included open-ended questions (qualitative analysis). Any obvious spelling errors were corrected during data analysis.

Continuous quality monitoring

The Fionet™ portal allows for storage of all data related to RDT programme(s) using the Deki Reader. This data can be monitored centrally on a continuous basis. The capabilities of the portal were examined to determine the extent of continuous quality monitoring (audit indicators of test and algorithm quality) available to authorised individuals (e.g. region managers). Both the devices and the web portal are accessed through a registered user name and password based on access authorisation determined at study commencement, ensuring that data security is maintained. Only authorised personnel (Fio technical software developers, clinical and laboratory research scientists, and research program managers) had access to anonymised results.

Statistical analysis

Data collected through the Fionet™ portal were downloaded as Microsoft® Excel (Microsoft® Corporation, Redmond, WA, USA) files and included study number, date of processing, HCW login, RDT used, visual interpretation and automated interpretation (both including HIV-1 and HIV-2 if included on the RDT). The visual RDT interpretation (SOC) was considered the reference for all analyses. All data was adjudicated by a Fio expert, in order to improve the analysis software. Performance evaluation analyses of the Deki Reader result outputs compared to visual interpretation (considered the reference standard) included concordance, sensitivity and specificity, and inter- and intra-device result reproducibility (only determined in the laboratory setting). Concordance included invalid specimens, but excluded errors and specimens that were not processed, while sensitivity and specificity only included specimens with a valid HIV positive or negative result. Acceptability for reproducibility, concordance, sensitivity and specificity was set at ≥98%. Statistical analyses were performed using Microsoft® Excel 2016, Stata version 12-SE (StataCorp LLC, College Station, TX, USA) and MedCalc (version 19.1.5, MedCalc Software, Ostend, Belgium). The HCW user experience feedback (quantitative and qualitative, as described above applying the Likert score and descriptive experiences) was captured in Microsoft® Excel 2010 tables and positive or negative experiences summarised using a heat map approach.

Results

Laboratory evaluation

The laboratory evaluations of both the Deki Reader v100 and the Deki Reader v200 showed that automated RDT analysis was comparable with SOC (visual RDT analysis). Overall precision (Table 1) was 98.3% for both intra- and inter-device precision for the Deki Reader v100, with overall sensitivity of 98.7% (95% CI: 93.2–100) and specificity of 96.2% (95% CI: 80.4–99.9), across 121 RDTs processed and uploaded to Fionet™. A number of results (n = 12) were not uploaded (connectivity) and there were two errors recorded. If HCW entry error (n = 1), which caused a false positive result when the Deki Reader was compared to SOC, is taken into account, the intra- and inter-device precision improves to 99.2%. The intra- and inter-device precisions were 99.3 and 99.2% respectively for the Deki Reader v200. The Deki Reader v200 intra-device sensitivity was 100% (95% CI: 95.2–100) with specificity of 98.7% (95% CI: 92.8–100), and inter-device sensitivity was 98.5% (95% CI: 92.1–100) with 100% specificity (95% CI: 95.1–100). The overall intra-device (n = 150) sensitivity and specificity were 100% (95% CI: 95.2–100) and 98.7% (95% CI: 92.8–100) respectively, while inter-device (n = 142) sensitivity and specificity were 98.5% (95% CI: 92.1–100) and 100% (95% CI: 95.1–100). If HCW entry error in the Deki Reader v200 evaluation was addressed, similarly to the Deki Reader v100 evaluation, the intra-device precision improved to 100%. Discordant results (n = 1 per evaluation) were linked to the presence of artefact in the region of the RDT HIV-2 test line, which affected the overall HIV status (Table 2). Similar artefact was observed in several specimens (n = 33 concordant and n = 6 discordant with SOC), but did not affect the overall HIV status.

The concordance analysis of laboratory specimens (Table 3) was performed on 774 different specimens separated across different RDTs for the Deki Reader v100 evaluation. Acceptable overall concordance between the Deki Reader v100 and SOC results was observed both
before (98.1%) and after (99.5%) data adjudication, and across all RDTs analysed: First Response® HIV 1–2-0: 100%, Alere Determine™ HIV-1/2 Ag/Ab Combo: 98.8% and Uni-Gold™ HIV: 99.6%. Overall sensitivity and specificity for the v100 were 99.5% (95% CI: 98.2–99.9) and 99.4% (95% CI: 97.9–99.9) respectively, with the sensitivity and specificity of individual RDTs also acceptable.

Two positive specimens by SOC (Uni-Gold HIV) were recorded as errors by the Deki Reader v100; in both cases the error was caused by invalid control line. Four specimens were misclassified (2/341 negative specimens and 2/397 positive specimens). The two false negative results (Alere Determine™ HIV 1/2 Ag/Ab Combo RDT (n = 1) and Uni-Gold™ HIV RDT (n = 1)) were caused by target capture lines with a width < 30% of the cassette window; the standard Deki Reader configuration is that a line is not present if its width is < 50% of the window. The two false positive results (both Alere Determine™ HIV 1/2 Ag/Ab Combo RDT) were the direct result of air bubbles in the membrane at the time of analysis (15 min), which were misinterpreted as test lines. All errors and misclassifications were related to the individual RDT used, rather than to the performance of the Deki Reader v100.

The Deki Reader v200 concordance (Table 3) was evaluated using 158 specimens processed on three different RDTs. Concordance in comparison to SOC was lower than expected (96.8%), with nine (1.9%) false positive results recorded, and only the First Response® HIV 1–2-0 displaying concordance above the acceptable limit (98.7%). The One Step Anti-HIV (1&2) concordance was 94.9%, primarily due to the Deki Reader v200 reporting invalid control line position (n = 6). When this data was adjudicated (increased flexibility in the location of the target line within the RDT), the One Step Anti-HIV (1&2) concordance improved to 98.6% and overall concordance improved to 98.0% (acceptable). The HIV 1/2/0 Tri-Line concordance was 96.8%, with five false positive classifications by the Deki Reader v200; this may indicate that refinement of the new software is required.

### Table 1: Precision of the Deki Reader using laboratory derived specimens

| Deki Reader Version | RDT brand | Result compared to SOC | Concordance n (%) |
|---------------------|-----------|------------------------|-------------------|
|                     |           | HIV positive True   | False | HIV negative True | False | Deki & HCW invalid (true invalid) |
| V100 (n = 45)       | First Response® HIV-1-2-0 | 25 d 1 16 – – | 41 (97.6) |
|                     | Determine™ HIV-1/2 Ag/Ab Combo | 29 – – 16 45 (100) |
|                     | Uni-Gold HIV | 24 – 9 d 1 – | 33 (97.1) |
| Overall (n = 121)   |           | 78 1 25 1 16 | 119 (98.3) |
| V200 (n = 50)       | First Response® HIV-1-2-0 | 25 – 25 – – | 50 (100) |
|                     | One Step Anti-HIV (1&2) | 25 e 1 24 – – | 49 (98.0) |
|                     | HIV 1/2/0 Tri-Line | 25 – 25 – – | 50 (100) |
| Overall (n = 150)   |           | 75 1 74 – – | 149 (99.3) |

*Numbers indicate concordant invalid results from both Deki Reader and HCW. No false invalid specimens were observed.

*Concordance includes invalid specimens, but excludes errors and specimens that were not processed.

*Specimens not uploaded to Fionet™ (First Response® HIV 1–2-0 n = 3; Uni-Gold HIV n = 9).

*Presence of artefact.

*HCW transcription error.

*Specimens not captured by HCW (First Response® HIV-1-2-0 n = 4; HIV 1/2/0 Tri-Line n = 4).

*Deki Reader error (n = 2).
### Table 2 HIV-1 and HIV-2 results (RDTs with separate target lines for HIV-1 and HIV-2)

| Deki Reader Version | RDT brand | HIV-1 Result | HIV-2 Result |
|---------------------|-----------|--------------|--------------|
|                     |           | Positive True | False False | Concordance n (%) |
|                     |           | Positive True | False False | Concordance n (%) |
|                     |           | Positive True | False False | Concordance n (%) |

#### Intra-instrument reproducibility (5 specimens read 3 times on the same instrument (n = 3 instruments))

|                     | First Response® HIV-1-2-0 | 12 | 0 | 30 | 0 | 42 (100) |
|                     | HIV 1/2/0 Tri-Line         | 25 | 0 | 25 | 0 | 50 (100) |

#### Intra-instrument reproducibility (5 specimens read 5 times on the same instrument)

|                     | First Response® HIV-1-2-0 | 12 | 0 | 30 | 0 | 42 (100) |
|                     | HIV 1/2/0 Tri-Line         | 21 | 0 | 25 | 0 | 46 (100) |

#### Inter-instrument reproducibility (5 specimens read across 3 instruments (3 reads per instrument))

|                     | First Response® HIV-1-2-0 | 110 | f | 5 | 43 | 0 | 153 (96.8) |
|                     | HIV 1/2/0 Tri-Line         | 112 | f | 7 | 39 | 0 | 151 (95.6) |

#### Laboratory-derived specimen concordance (n = 158)

|                     | First Response® HIV-1-2-0 | 110 | f | 5 | 43 | 0 | 153 (96.8) |
|                     | HIV 1/2/0 Tri-Line         | 112 | f | 7 | 39 | 0 | 151 (95.6) |

#### Summary

- Concordance includes invalid specimens, but excludes errors and specimens that were not processed.
- Presence of artefact: discordant HIV-2 positive results affecting overall HIV result.
- Presence of cross reactivity: concordant HIV-2 positive results (this was linked to two specimens).

### Table 3 Laboratory evaluation of the Deki Reader comparing device versus SOC results

| Deki Reader Version | RDT brand | Result compared to SOC | HIV positive | HIV negative | Sensitivity % (95%CI) | Specificity % (95%CI) | Deki & HCW invalid (true) | Deki invalid (false) | Concordance n (%) |
|---------------------|-----------|------------------------|--------------|--------------|-----------------------|------------------------|--------------------------|----------------------|------------------|
|                     |           | HIV positive True False | HIV negative True False |              |                       |                        |                         |                      |                  |
|                     |           | 128 – 118 –            |              | 100 (97.2–100) | 100 (96.9–100) | 7 – 253 (100) |
|                     | First Response® HIV-1-2-0 (n = 253) | 135 | 2 | 94 | d | 1 | 99.3 (96.0–100) | 97.9 (92.7–99.8) | 27 – 256 (98.8) |
|                     | Determine™ HIV-1/2 Ag/Ab Combo (n = 259) | 132 | – | 127 | d | 1 | 99.3 (95.9–100) | 100 (97.1–100) | – – 259 (99.6) |
|                     | Uni-Gold HIV (n = 262) | Overall (n = 772) | 395 | 2 | 339 | 2 | 99.5 (98.2–99.9) | 99.4 (97.9–99.9 | 34 – 768 (99.5) |
|                     |           | Overall (n = 474) | 336 | 9 | 122 | – | 100 (98.9–100) | 93.1 (87.4–96.8) | 1 6 459 (96.8) |

- Concordance includes invalid specimens, but excludes errors and specimens that were not processed. Sensitivity and specificity only includes specimens that gave a valid positive or negative result.
- Deki Reader data was adjudicated by Fio as part of the process to optimise the output data (software optimisation).
- Air bubble over control line, linked to RDT.
- Line < 50% of width, software adjustments required.
- Deki Reader v100 error (n = 2)
- Deki Reader v200 invalid control line.
TriLine RDT specificity less than 90% (88.6% (95% CI: 75.4–96.2)).

Field evaluation

Nineteen (82.3%) trained HCW participated in the first field evaluation, with 3159 RDT results successfully uploaded to Fionet™. On average 527 results were uploaded per month, but with a wide range (153, 1573), and the majority were uploaded during July 2017. The average number of records uploaded in <10 min was 95.8% (range: 94.2, 98.0), and all records were uploaded within a maximum of seven days. The quality data transmission (QDT, 10% of records) was consistently 100%. No battery failures were experienced over the course of the study and 90% (n = 18) of Deki Reader v100 devices showed no decrease in functionality, However, 10% (n = 2) devices, both placed with mobile units, failed to function optimally towards the end of the evaluation.

Thirty-six (69.2%) of HCW trained participated in the second field trial (concordance evaluation), although thirteen HCW processed less than ten specimens. Four HCW processed more than 400 specimens, ten processed between 300 and 100 specimens, and a further nine HCW processed between 50 and 100 specimens. A total of 4460 patients were enrolled in this field evaluation, 2463 (55.2%) under Algorithm 1 and 1997 (44.8%) under Algorithm 2. After data adjudication, concordances were 99.3 and 96.5% (screening), and 99.7 and 100% (confirmatory) for Algorithms 1 and 2 respectively (Table 4). Overall sensitivity and specificity across all specimens were 99.8% (95% CI: 99.2–100) and 97.7% (95% CI: 97.2–98.2) respectively, with decreased Deki Reader specificity observed for the HIV 1/2/0 TriLine RDT which was common to both algorithms (93.8% as the confirmatory RDT in Algorithm 1 and 96.1% as the screening RDT in Algorithm 2).

There were a number (1.4%, n = 32) of invalid (no result by both SOC and automated analysis) Advanced Quality Anti-HIV (1&2) RDTs in Algorithm 1. Furthermore, 15 false positive screening RDTs were recorded, of which twelve were true negative results and three should have been repeated: in one case the RDT strip had shifted (Fig. 3a) and in the remaining two cases the specimen did not move completely through the RDT membrane; it was proposed that insufficient buffer was added to the RDT, which could indicate HCW retraining is required (Fig. 3b). One false positive confirmatory RDT compared to SOC was recorded and could be linked to HCW analysis error, with the specimen not moving through the RDT membrane (Fig. 3c). A high number of false positive (3.6%) HIV 1/2/0 Tri-Line RDTs were recorded under algorithm 2; 53/64 were linked to high levels of artefact in the region of the HIV-2 target line (Fig. 3d), which skewed the automated analysis, while the remaining 11 were true negative results. Specimens which were not analysed by the Deki Reader v100 are summarised in Fig. 4. The majority of errors were linked to the RDT not being analysed within the

### Table 4 Clinical evaluation of the Deki Reader v100

| RDT brand | Result compared to SOC | HIV positive | HIV negative | Sensitivity % (95%CI) | Specificity % (95%CI) | Deki & HCW invalid (true) | Concordance n (%) | Error/not analysed (Deki) |
|-----------|------------------------|--------------|--------------|-----------------------|-----------------------|--------------------------|---------------------|--------------------------|
| **Algorithm 1: Screening: Advanced Quality Anti-HIV (1&2); Confirmatory: HIV 1/2/0 Tri-Line** | | | | | | | | |
| Advanced Quality Anti-HIV (1&2) (n = 2463) | | 386 | 15 | 1817 | 2 | 99.5 (98.2–99.9) | 99.2 (98.7–99.5) | 32 | 2252 (99.3) | 196 |
| HIV 1/2/0 Tri-Line (n = 352) | | 261 | 1 | 15 | – | 100 (98.6–99.8) | 93.8 (69.8–99.8) | 5 | 281 (99.7) | 70 |
| **Algorithm 2: Screening: HIV 1/2/0 Tri-Line Confirmatory: First Response® HIV-1-2-0** | | | | | | | | |
| HIV 1/2/0 Tri-Line (n = 1997) | | 153 | 64 | 1588 | – | 100 (97.6–100) | 96.1 (95.1–97.0) | – | 1741 (96.5) | 192 |
| First Response® HIV 1–2–0 (n = 129) | | 115 | – | 1 | – | 100 (96.8–100) | 100 (2.5–100) | 1 | 117 (100) | 12 |
| **Overall RDTs (n = 4941)** | | 915 | 80 | 3421 | 2 | 99.8 (99.2–100) | 97.7 (97.2–98.2) | 38 | 4374 (97.8) | 470 |

*Concordance includes invalid specimens, but excludes errors and specimens that were not analysed. Sensitivity and specificity only includes specimens that gave a valid positive or negative result

**SOC positive and Deki Reader invalid. Specimen was incorrectly processed and reported; this a HCW error. See Fig. 3c**

(1&2)
allowed timeframe \((n = 315, 67\%)\) and to blood being added to the buffer well \((n = 107, 22.8\%)\), which was only observed with the Advanced Quality Anti-HIV (1&2) RDT. Both of these are HCW errors, although the former was reported by HCW to be caused by the Deki Reader v100 RDT drawer not detecting closure in multiple instances.

HCW surveys were completed post-training and post-field evaluation, with 19 HCW (100\%) participating in the first field evaluation feedback and 34 HCW (65.4\%) participating in the second field evaluation feedback (Fig. 5). Overall, HCWs were more ambivalent about using the device after several months of use in the field, with many indicating that it slowed the clinic workflow. The most frequent end-user complaint (100 and 91.2\% from the first and second field evaluations respectively) was instrument suspension (‘freezing’). The size of the screen, even when using stylus pens, and the lack of electronic complaint forms were common complaints during the first field evaluation. Two device manufacture issues reported during the second field evaluation were both linked to problematic result capture by the Deki Reader v100: (1) the RDT drawer did not detect closure immediately and the result was not then captured as processing time was exceeded and (2) the marker pens used to write patient initials on the RDT absorbed into the RDT cassette plastic between the initial RDT image capture and the result capture (after processing time), causing the Deki Reader v100 to reject the RDT as a different specimen. HCW at high volume testing sites also stated that the use of the Deki reader slowed the workflow and this led to patient complaints. Based on HCW feedback, Fio Corporation redesigned the Deki Reader with an improved camera, a larger screen and increased stability, and also removed the need for third party part supply. The Deki Reader v200 showed good robustness and battery life in the laboratory, but evaluation of device robustness in the field is ongoing.

### Continuous quality monitoring

The Fionet™ portal enabled centralised monitoring of the devices, and also of individual HCW and clinics, which can support early detection of breaches in protocol. For example, in the case of the RDT drawer not closing, two HCW using the same instrument (consequently and at different sites) were responsible 90.0 and 89.5\% of these errors, which comprised 30\% of time expired errors. Once the drawer was replaced both HCW were not linked to similar error issues. This type of incident can be addressed timeously to ensure continued quality at all testing sites, through assessment of HCW, devices and clinic procedures. Weekly encounters at clinics are tracked, as are error rates across all sites. Lastly, the actual RDTs can be monitored for lot errors; on the recommendation of the field trial managers, lot numbers can now be recorded on the devices.

### Target product profile

A TPP was designed based on the existing TPP for viral load monitoring in resource limited settings [34] and on knowledge gained through experience in the field, in consultation with Deki Reader training staff. The Deki Reader v100 (laboratory and field evaluations) and Deki Reader v200 (laboratory evaluation) showed acceptable performance, meeting either minimal or optimal criteria throughout. Key criteria met, beyond sensitivity and specificity, include: (1) the ability to evaluate and capture RDTs for different diseases and from different suppliers (although ‘software training’ is required); (2) connectivity to a central database (in this case www.fionet.com) through a local mobile data service provider; (3) a robust, electricity-independent system with rechargeable batteries; and (4) the ability to log multiple patients concurrently, yet ensure that the correct RDT is analysed for each patient.

### Discussion

The HTS programme in South Africa has been expanding since 2000 [35] and RDT use is significant. Notable
landmark steps include the 2010 HTS guideline amendments to allow non-healthcare workers to test for HIV using RDTs [36], the launch of nurse-initiated ART [37] and, most recently, UTT [9] and self-testing guidelines [38]. Quality HIV screening has always been important to patient well-being and highlights the need for correctly administered and evaluated RDTs [1, 39]. Next steps should thus include improved quality monitoring, improved surveillance to enable program optimisation and improved management of patient linkage to care. Devices that are able to monitor the testing process, automatically evaluate the RDT and upload data to a centralised system can address these gaps and potentially standardise the quality of care across a variety of

Fig. 4 Summary of RDTs (n = 470) unable to be analysed by the Deki Reader v100 during the clinical concordance field evaluation. In 10.5% of RDTs, the Deki Reader gave an error flag (unable to be analysed) rather than a result. These flags can be used for continuous quality monitoring of HCW performance and RDT quality. Under Algorithm 1 there were 266 specimens that were not analysed, of which 144 were not analysed within the required time period (HCW error). A high number (n = 107) of the Advanced Quality™ Rapid HIV (1&2) RDT were not analysed as the blood was added to the buffer well (HCW error). The remaining errors were found on the RDT (4 with no control line and 11 with irregular test or control lines). Similarly, under Algorithm 2 (n = 204), 171 flags indicated that the RDT had not been analysed within the required time period (HCW error*), with a slightly higher number of RDT errors (11 with no control line and 22 with irregular control or test lines). *While these errors are linked to HCW performance, in this case it was determined that the majority of these errors occurred on one Deki Reader, where the device drawer did not detect closure, leading to the allowable timeframe expiring; once the drawer was fixed, this error was not noted again.
**Fig. 5** Summary of HCW feedback (pre- and post-field evaluation). HCWs completed feedback forms after Deki Reader v100 training (pre-evaluation) and post-field evaluation for both the robustness ($n=19$) and concordance ($n=34$) evaluations. The feedback results are summarised as a heat map: green = positive response, yellow = neutral response, red = negative response. The forms consisted of defined comments/questions and free text provided by the HCWs.

(a) The defined comments/questions used a Likert scale and the HCW were asked to agree (positive response) or disagree (negative response), or to define as easy (positive response) or difficult (negative response), with a neutral option also available. There was more HCW ambivalence over the use of the technology post the field evaluation (increased red/yellow).

(b) The most frequently recorded comments are shown, and coded as positive (green) or negative (red) responses out of the total number of HCW per phase. No comments were provided for the pre-evaluation questionnaire in the robustness phase. Notes: 1The functional check was a manufacturer designed RDT to be used to ensure that the instrument was functioning correctly at the start of each day. 2The pens used to write patient initials on the RDT absorbed into the RDT cassette plastic between the initial RDT image capture and the result capture (after processing time), causing the Deki Reader v100 to reject the RDT as a different specimen.
settings, ranging from true remote POC through to urban clinics. A central database allows all sites and RDT testers to be monitored in real-time, meaning that anomalies in the system, such as RDT batch errors and decreased staff proficiency, can be detected early [24]. The readily available real-time data allows for effective monitoring and surveillance of the program and remote management of HCWs, including targeted identification for retraining, which was one of the areas identified by Johnson et al. (2017) [1], and the centralised storage of countrywide HIV screening results allows data to be instantly available for HIV prevalence monitoring. Although this study focused on feasibility and RDT reader performance, the quality indicators observed did indicate gaps in the field, which are not otherwise recorded or monitored. The centralisation of field data can potentially enable managerial oversight of clinics, HCW and RDTs in the field for follow-up, corrective action and quality monitoring of the HTS programme, as well as for optimised HIV surveillance.

This study included a number of evaluations. Sensitivity and specificity between the visual and automated RDT analysis showed variability, while concordance was consistently acceptable. The laboratory evaluations of both the Deki Reader v100 and the updated Deki Reader v200, showed intra- and inter-device precision of > 99%. Similarly, concordance was consistently above 95% (minimal criterion) and, excluding HCW errors and artefact, close to 99%. Concordance in the field was also high, 99.3 and 99.7% for screening and concordance respectively for Algorithm 1, and 96.5% (screening) and 100% (concordance) for Algorithm 2. The decreased screening concordance under Algorithm 2 was primarily caused by high levels of artefact present in the region of the HIV-2 target line on the HIV 1/2/0 Tri-Line RDT, which skewed the automated analysis. Options to overcome this are being investigated further by Fio Corporation, and the addition of lot number recording to the software was recommended to determine whether specific RDT batches were affected. The artefact could also be linked to imperfect processing, which would indicate a need for HCW retraining; review of RDTs centrally (as is not currently possible) would allow this to be detected rapidly. The processing error rate (9.5%) was slightly higher than that reported by Kalinga and colleagues (2018) for malaria RDTs [24], but was notably linked to the RDT not being assessed in the allowable time period. This did highlight HCW retraining, but was also found to relate to a drawer not closing; once the drawer was replaced, this error decreased. These, and examples described in the results section, show how the Fionet™ portal, when optimally monitored, can trigger interventions remotely to allow rapid corrective action in the field, be the errors linked to HCW, RDTs or to the Deki Reader itself. Recent evaluation of the Deki Reader v100 to monitor malaria RDTs showed a 97% decrease in processing errors when using the device and applying quality monitoring through the Fionet™ portal [24]. Identification of these audit indicators (and their rate of monitoring: daily, weekly, monthly) and the responsibility of monitoring and reporting need to be defined within the laboratory and clinical interface ecosystem and responsibilities assigned, especially in large HIV programs.

In the field, the overall robustness, quality data capturing and connectivity, and record upload speed were good. The Deki Reader was able to capture and transmit reliable data for monitoring and evaluation purposes (100%), and to store patient results until data upload if no connectivity was available. Neither of these was previously widely possible when using RDTs for HIV diagnosis, with conventional data records being paper-based, although certain mobile phone-based applications have been suggested [40]. The reliability (100%) of the batteries show the potential of the Deki Reader as a tool for POC testing or outreach testing in rural areas, where limited access to electricity may be a problematic factor, provided that it is possible to recharge the device every two to three days. While the Deki Reader v100 was robust, the failure of two instruments (10%) in the mobile testing centres towards the end of the evaluation indicate a need for further assessment in mobile settings. Furthermore, it is concerning that all end-users reported system freezes. Suggestions for this were the use of third-party software, possibly intermittently clashing with the Deki Reader operating system, or a lack of random access memory and/or storage space. The Fio Corporation addressed these concerns by bringing the technology manufacture in-house with the Deki Reader v200, and ongoing field evaluations will determine if this problem has been corrected, which is vital before widespread rollout of the devices is feasible.

While the HCW were initially positive regarding the Deki Reader v100 improving their workflow, the end-user acceptance of the Deki Reader showed more ambivalence or dislike of the device in the post-evaluation surveys. The primary reasons for this were the system freezes, which have been addressed and will be re-examined during the Deki Reader v200 field evaluation, and that the Deki Reader will not allow a strip to be analysed prior to completion of the incubation period. While the extended analysis time does “irritate the patient as they don’t want to wait”, ensuring proper adherence to protocols does ensure the provision of high quality HTS services. A recent study showed that many HCW read the results too early and misdiagnose patients [12], in addition to the subjective nature of visual RDT interpretation [24]. Patient acceptance of the device should also be formally analysed in future studies, as
comments from patients were received via the HCW, indicating that patients did not like the time taken to log data (particularly with system freezes) or that they had to wait the recommended length of time before results were shared.

It is proposed that the Deki Reader may also enhance HTS tester performance through the on-board systematic guidance and quality control checks. The use of both the paper-based records and the Deki Reader v100 in the field evaluation did increase the HCW time burden, which may have influenced their opinions, and ideally paper-based registers will be discontinued if automated, connected RDT analysers are implemented. However, the registers were useful in the data analysis, as both field and laboratory staff reported that if the incorrect visual result was entered onto the Deki Reader (both versions), there was no option to correct it. When comparing the paper-based results to the RDT images and entered visual results, it was noted that the majority of discordant specimens (Deki Reader compared to SOC) were not truly discordant. Based on this, the software is being modified to allow result correction (visual) prior to automated analysis reporting. The HCW will also have the option to dispute the automated result, such as in the case of artefact, although this is still under development.

The Deki Reader v100 met the majority of criteria suggested for the TPP and the Deki Reader v200 will be similarly assessed in the field. The robustness of the device should be evaluated further in more stringent environments, including increased humidity and more extreme temperatures, and full costing analyses must be performed. Although not part of the TPP, it should be mentioned that the value of a fixed, rather than mobile, device is that the distance between the device camera and RDT, remains constant irrespective of the RDT. The closed chamber further standardises the light environment when an image is captured, irrespective of the surrounding environmental light conditions. The presence of artefact is being addressed, as this was the most worrying TPP criterion not met, albeit only with one RDT brand. However, ongoing software optimisation and HCW training, including repeating RDTs when artefact is visible, may address this issue.

It was noted that a potential limitation of the technology is that the introduction of any new RDT requires software modification, which requires time and validation prior to implementation. In addition, the RDT reader developer will require access to the new RDT to be used in the field and implementation partners need to be aware of time delays for technology optimisation. However, devices not locked to specific RDTs are important when using the device in different settings, with varying algorithms, RDT types and HTS protocols being required dependant on country needs. The ability of the Deki Reader to accept new software (pushed through to the device from a central point) and the flexibility of the software, as shown during the algorithm change mid-field evaluation, enables the device to adapt to the needs of the settings and allows the RDT market to remain competitive.

Lastly, with the increased availability of HIV self-testing, which is performed by the untrained layman, and the need for linkage to care for persons with a positive result [41, 42], the Deki Reader may also have a role beyond HTS clinics. An investigation into the acceptability of siting Deki Readers in private areas at selected pharmacies or similar for HIV self-testing could ensure better quality results and the option for results to be sent to a health-care provider. The device is simple to use and may be an alternative to downloading smartphone applications to submit self-processed RDTs for analysis. At a minimum, the delinked information could be available for surveillance purposes. Expanding the Fionet™ portal capability to incorporate geographic information systems mapping could be further valuable tool for program surveillance.

Conclusion

Contemporary technologies have the potential to enhance the provision of healthcare services, particularly at POC. The Deki Reader provides a means for continuous quality control and reliable quality assessment in rapid diagnosis of HIV using RDTs. This includes effective and efficient patient care and data capturing, as well as high connectivity capabilities, and the device has the potential to be deployed to rural areas of South Africa to optimise HTS coverage. The technology can also be deployed for HIV RDT monitoring in settings where the Deki Reader v100 already has a large footprint in the diagnosis of febrile malaria. However, ongoing and agile measures should be in place to mitigate against all end-user challenges to ensure continuous and consistent acceptability of the device throughout the HIV value chain.

Abbreviations

ART: Antiretroviral therapy; HCW: Health care worker; HIV: Human Immunodeficiency Virus; HTS: HIV testing services; NHLS: National Health Laboratory Service; PLWH: People living with HIV; POC: Point of care; QDT: Quality data transmission; RDT: Rapid diagnostic test; SEAD: Strategic Evaluation, Advisory & Development; SOC: Standard of care; TPP: Target product profile; UTT: Universal test and treat; WHO: World Health Organisation

Acknowledgments

We thank study participants and health care workers, without whom this evaluation would not have been possible; Dr. Leigh Berrie and Dr. Natasha Gous for initial protocol development and testing; Dr. Louise Gilbert (Themba Lethu Clinic), Thembakazi Mojozi (DREAMS-team) and their teams; site staff for their honest feedback on the use of the instrument in the field;
Portia Madumo for training of staff, and the Department of Health for permission to conduct this study in their clinics (Gauteng region).

Authors’ contributions
WS and LI designed the study. SJM was responsible for the management of the study, overseen by PDS. IS provided clinical oversight. LN and SJM analysed the data and interpreted the results with the help of LS, WS and PDS. LN drafted the paper, and LS, WS and PDS critically reviewed the paper. All authors read and approved the final manuscript.

Funding
The NPP/NHLS was a sub-recipient to the South African National Department of Health, on Global Fund to fight AIDS, tuberculosis and malaria funds (sub-recipient grant number: ZAC-C-NDOH), which funded study programme managers. Funding to provide grant-funded research staff salaries was received from (1) the South African Medical Research Council with funds received from the South African National Department of Health, and the UK Medical Research Council, with funds received from the UK Government’s Newton Fund under the UK/South Africa Newton Fund #015NEWTON TB; and from (2) the Bill & Melinda Gates Foundation through the Innovation in Laboratory Engineered Accelerated Diagnostics investment (grant number OPP1171455). The funders had no role in the study design, data analysis, manuscript writing, or decision to submit the study findings for publication. Investigational devices and RDTs were supplied by the Fio Corporation. Fio personnel had no role in study design, manuscript writing, or decision to submit the study findings for publication, but did assist in data adjudication.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to patient confidentiality, but are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethics approval for this evaluation was obtained from the University of the Witwatersrand (Johannesburg, South Africa) Human Research Ethics Committee: M150160. Specimens were considered to be residual and the corresponding author on reasonable request. Consent was obtained from each participant.

Consent for publication
Not applicable.

Competing interests
SJM was a consultant to the South African National Department of Health, on Global Fund to fight AIDS, tuberculosis and malaria funds (sub-recipient grant number: ZAC-C-NDOH). WS, LS and LN were supported by funding received from the South African Medical Research Council with funds received from the South African National Department of Health, and the UK Medical Research Council, with funds received from the UK Government’s Newton Fund under the UK/South Africa Newton Fund #015NEWTON TB; and by funding received from the Bill & Melinda Gates Foundation through the Innovation in Laboratory Engineered Accelerated Diagnostics investment (grant number OPP1171455).

Author details
1Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa. 2National Priority Programme, National Health Laboratory Service, Johannesburg, Gauteng, South Africa. 3BroadReach Consulting, Johannesburg, Gauteng, South Africa. 4Strategic Evaluation Advisory and Development Consulting, Johannesburg, Gauteng, South Africa. 5Right to Care, Johannesburg, Gauteng, South Africa.

Received: 10 April 2019 Accepted: 28 February 2020
Published online: 04 May 2020

References
1. Johnson CC, Fonner V, Sands A, Ford N, Obermeyer CM, Tsui S, et al. To err is human, to correct is public health: a systematic review examining poor quality testing and misdiagnosis of HIV status. J Int AIDS Soc. 2017;20(Suppl 6):21755.
2. Joint United Nations Programme for HIV/AIDS. 90–90—90—an ambitious treatment target to help end the aids epidemic. Available from: http://www.unaids.org/en/resources/documents/2014/90-90-90. Accessed 07 Sept 2017.
3. UNAIDS. Global AIDS Update 2018: Miles to go. Available from: www.unaids.org/en/20180718_GR02018. Accessed 28 July 2018.
4. Grinsztejn B, Hosseinipour MC, Ribaudo H, Swindells S, Enos J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HOPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281–91.
5. Danel C, Moh R, Gailbard D, Badje A, Le Carrou J, Ouassa T, et al. The TEMPRAANO ANRS 12136 study group. A trial of early Antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.
6. Lundgren JD, Babiker AG, Gordin F, Emsey S, Grund B, Sharma S, et al. INSIGHT START study group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
7. World Health Organisation. Consolidated Guidelines on the Use of Antiretroviral Drugs forTreating and Preventing HIV Infection: Recommendations for a Public Health Approach, 2nd Edition. Geneva: World Health Organisation; 2016.
8. World Health Organisation. Treat All: policy adoption and implementation status in countries. In: World Health Organisation, editor. Geneva, 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/326035/WHO-CDS-HIV-19.20-engpdfu=1. Accessed 03 Mar 2020.
9. South African National Department of Health. National HIV Testing Services: Policy. Pretoria, 2016. Available from: https://www.nacoboa.org.za/wp-content/uploads/2016/05/HIV-Policy-guide.pdf. Accessed 22 Feb 2016.
10. Gray RH, Makumbi F, Sewadda D, Lutalo T, Nalugoda F, Opendi P, et al. Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ. 2007;335(7612):188.
11. Moodley D, Moodley P, Nbadzbanda T, Esterhuizen T. Reliability of HIV rapid tests is user dependent. South African medical journal =. Suid-Afrikaanse tydskrif vir geneeskunde. 2008;98(9):707–9.
12. SEAD. Analysis of POCT/VCT performed at South African primary health care clinics. 2010. Available from: http://www.sead.co.za/downloads/POCT-clinics-2011.pdf. Accessed 5 Jul 2016.
13. Mwisongo A, Peltzer K, Mohlabane N, Tutshana B. The quality of rapid HIV testing in South Africa: an assessment of testers’ compliance. Afr Health Sci. 2016;16(3):646–54.
14. WHO. Guidelines for assuring the accuracy and reliability of HIV rapid testing: applying a quality system approach. Available at: http://www.who.int/tb/research/2016/tuberculosis-quality-assurance.pdf. Accessed 5 January 2017. Geneva, Switzerland, 2005.
15. World Health Organisation. Consolidated Guidelines on HIV Testing Services: SC - Consent, Confidentiality, Counselling, Correct Results and Connection. Available at: https://www.ncbi.nlm.nih.gov/books/NBK316021/pdf/Bookshelf_NBK316021.pdf. Accessed 5 January 2018. Geneva, Switzerland: World Health Organisation, 2015.
16. Parekh BS, Anayywu J, Patel H, Downer M, Kalou M, Gichuru C, et al. Dried tube specimens: a simple and cost-effective method for preparation of HIV proficiency testing panels and quality control materials for use in resource-limited settings. J Virol Methods. 2010;163(2):295–300.
17. Parekh BS, Kalou MB, Alemenyi O, Ou CY, Gyeshy-Damet GM, Nkengasong JN. Scaling up rapid HIV testing in developing countries: comprehensive approach for implementing quality assurance. Am J Clin Pathol. 2010;134(4):675–84.
18. Fonjungo PN, Boeras DJ, Zeh C, Alexander H, Parekh BS, Nkengasong JN. Access and quality of HIV-related point-of-care diagnostic testing in Global Health programs. Clin Infect Dis. 2016;62(3):369–74.
19. Mwangala S, Musonda KG, Monze M, Musukwa KK, Fylkesnes K. Accuracy in HIV rapid testing among laboratory and non-laboratory personnel in Zambia: observations from the national HIV proficiency testing system. PLoS One. 2016;11(1):e0146700.
20. UNAIDS. UNAIDS Data 2018. Available from: http://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf. Accessed 11 November 2018. Geneva, Switzerland: Joint United Nations Programme for HIV/AIDS; 2018. Contract No.: 11 September 2018.
21. STATs SA. Mid-year population estimates 2018. Available at: http://www.stats.gov.za/publications/P0302/P030202018.pdf. Accessed 25 July 2018. Pretoria, South Africa.
22. Jani IV, Peter TF. How point-of-care testing could drive innovation in global health. N Engl J Med. 2013;368(24):2319–24.
23. Wedderburn CJ, Murtagh M, Taskin L, Peeling RW. Using electronic readers to monitor progress toward elimination of mother-to-child transmission of HIV and syphilis: an opinion piece. Int J Gynaecol. 2015;130(Suppl 1):S58–3.
24. Kalinga AK, Ishengoma DS, Kavishe R, Temu L, Mswanya C, Mwavaza C, et al. The use of Fionet technology for external quality control of malaria rapid diagnostic tests and monitoring health workers’ performance in rural military health facilities in Tanzania. PLoS One. 2018;13(12):e0208385.

25. Oyet C, Roh ME, Kiwanuka GN, Onikiziba P, Wade M, Parkh S, et al. Evaluation of the Deki reader, an automated RDT reader and data management device, in a household survey setting in low malaria endemic southwestern Uganda. Malar J. 2017;16(1):449.

26. Soti DO, Kinoti SN, Omar AH, Logedi J, Mwendwa TK, Hirji Z, et al. Feasibility of an innovative electronic mobile system to assist health workers to collect accurate, complete and timely data in a malaria control programme in a remote setting in Kenya. Malar J. 2015;14:430.

27. Herrera S, Vallejo AF, Quintero JP, Arevalo-Herrera M, Cancino M, Ferro S. Field evaluation of an automated RDT reader and data management device for Plasmodium falciparum/Plasmodium vivax malaria in endemic areas of Colombia. Malar J. 2014;13:87.

28. Shekalaghe S, Cancino M, Mavere C, Juma O, Mohammed A, Abdulla S, et al. Clinical performance of an automated reader in interpreting malaria rapid diagnostic tests in Tanzania. Malar J. 2013;12:141.

29. Adah P, Maduka O, Obasi O, Doherty O, Oguntuyi S, Seadon K, et al. The role of the Deki reader in malaria diagnosis, treatment and reporting: findings from an Africare pilot project in Nigeria. Malar J. 2018(17):221.

30. Kalinga AK, Mwavaza C, Chiduo S, Mswanya C, Ishengoma DI, Francis F, et al. Comparison of visual and automated Deki reader interpretation of malaria rapid diagnostic tests in rural Tanzanian military health facilities. Malar J. 2018;17(1):214.

31. Laktabai J, Platt A, Menya D, Turner EL, Aswa D, Kinoti S, et al. A mobile health technology platform for quality assurance and quality improvement of malaria diagnosis by community health workers. PLoS One. 2018;13(2):e0191968.

32. Ansumana R, Dariano DFR, Jacobsen KH, Leski TA, Taitt CR, Lamin JI, et al. Prevalence of markers of HIV infection among febrile adults and children in Bo, Sierra Leone. 2012-2013. BMC Res Notes. 2013;10(1):565.

33. The International Diagnostics Centre. TARGET PRODUCT PROFILE: POINT-OF-CARE HIV VIRAL LOAD TEST. Available from: http://www.idc-dx.org/resources/target-product-profile-point-of-care-hiv-viral-load-test. Accessed 10 February 2019.: London School of Tropical Medicine and Hygiene, London, United Kingdom, 2013.

34. South African National Department of Health. HIV/AIDS/STDs Strategic Plan for South Africa. Available at: https://www.gov.za/sites/www.gov.za/files/national%20strategic%20plan%20on%20hiv%20aids%20and%20stds_2017.pdf. Accessed 5 January 2017.

35. South African National Department of Health. The South African Antiretroviral Guidelines 2010. In: South African National Department of Health, editor. Pretoria; 2010. Available from: https://apps.who.int/medicinedocs/documents/s19153en/s19153en.pdf. Accessed 03 Mar 2019.

36. South African National Department of Health. National Strategic Plan on HIV, STIs and TB 2012–2016. Available at: https://www.gov.za/sites/www.gov.za/files/national%20strategic%20plan%20on%20hiv%20aids%20and%20stds%20on%20hiv%20aids%20and%20tb%202012_2016.pdf. Accessed 03 Mar 2019.

37. South African Clinicians’ Society. Guideline: South African HIV Self-Testing Policy and Guidance Considerations. A supplement to the National HIV Testing Services Policy 2016. Available at: http://www.sahivsoc.org/Files/Self%20Testing%20Guidelines_2017_WEB.pdf. Accessed 5 January 2017.

38. Fonjungo PN, Osmanov S, Kuritsky J, Ndihokubwayo JB, Bachanas P, Peeling RW, et al. Ensuring quality: a key consideration in scaling-up HIV-related point-of-care testing programs. Aids. 2016;30(8):1317–23.

39. Mudanyali O, Dimitrov S, Sikora U, Padmanabhan S, Navruz I, Ozcan A. Integrated rapid-diagnostic-test reader platform on a cellphone. Lab Chip. 2012;12(15):2678–86.

40. Indravudh PP, Chokko AT, Corbett EL. Scaling up HIV self-testing in sub-Saharan Africa: a review of technology, policy and evidence. Curr Opin Infect Dis. 2018;31(1):14–24.

41. Witzel TC, Rodger AJ. New initiatives to develop self-testing for HIV. Curr Opin Infect Dis. 2017;30(1):50–7.